- Home
- SONM vs NXTC Comparison
SONM vs NXTC Comparison
Compare SONM & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONM
- NXTC
- Stock Information
- Founded
- SONM 1999
- NXTC 2015
- Country
- SONM United States
- NXTC United States
- Employees
- SONM N/A
- NXTC N/A
- Industry
- SONM Telecommunications Equipment
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- SONM Telecommunications
- NXTC Health Care
- Exchange
- SONM Nasdaq
- NXTC Nasdaq
- Market Cap
- SONM 12.6M
- NXTC 12.8M
- IPO Year
- SONM 2019
- NXTC 2019
- Fundamental
- Price
- SONM $0.54
- NXTC $5.12
- Analyst Decision
- SONM
- NXTC Strong Buy
- Analyst Count
- SONM 0
- NXTC 2
- Target Price
- SONM N/A
- NXTC $25.50
- AVG Volume (30 Days)
- SONM 409.9K
- NXTC 318.4K
- Earning Date
- SONM 08-08-2025
- NXTC 08-07-2025
- Dividend Yield
- SONM N/A
- NXTC N/A
- EPS Growth
- SONM N/A
- NXTC N/A
- EPS
- SONM N/A
- NXTC N/A
- Revenue
- SONM $57,917,000.00
- NXTC N/A
- Revenue This Year
- SONM $127.68
- NXTC N/A
- Revenue Next Year
- SONM N/A
- NXTC N/A
- P/E Ratio
- SONM N/A
- NXTC N/A
- Revenue Growth
- SONM N/A
- NXTC N/A
- 52 Week Low
- SONM $0.53
- NXTC $2.69
- 52 Week High
- SONM $6.38
- NXTC $19.80
- Technical
- Relative Strength Index (RSI)
- SONM 35.10
- NXTC 48.99
- Support Level
- SONM $0.54
- NXTC $4.75
- Resistance Level
- SONM $0.60
- NXTC $5.23
- Average True Range (ATR)
- SONM 0.04
- NXTC 0.31
- MACD
- SONM 0.00
- NXTC 0.02
- Stochastic Oscillator
- SONM 4.59
- NXTC 53.28
About SONM Sonim Technologies Inc.
Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.